Novogene - About the company
Novogene is a deadpooled company based in Beijing (China), founded in 2011. It operates as a Provider of genomic services and solutions. The company has 809 active competitors, including 95 funded and 85 that have exited. Its top competitors include companies like Strand Life Sciences, Tessera Therapeutics and BGI.
Key Metrics
Founded Year
2011
Location
Beijing, China
Stage
Deadpooled
Ranked
1030th among 1094 competitors
Similar Companies
Sign up to download Novogene's company profile
Novogene's funding and investors
Novogene has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Novogene's Competitors and alternates
Top competitors of Novogene include Strand Life Sciences, Tessera Therapeutics and BGI. Here is the list of Top 10 competitors of Novogene, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Strand Life Sciences 2000, Bengaluru (India), Acquired | Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery | $34.9M | 73/100 | |
2nd | Tessera Therapeutics 2017, Cambridge (United States), Series C | Provider of new genome engineering technology for treating multiple diseases | $610M | 64/100 | |
3rd | Provider of services in genome sequencing | - | 64/100 | ||
4th | Hexagon Bio 2017, Menlo Park (United States), Series B | Provider of bioinformatics tools for the analysis of microbial genomic sequencing data | $206M | 63/100 | |
5th | AI-based oncology therapy plan solution for professionals | $43M | 60/100 | ||
6th | Singular Genomics 2016, San Diego (United States), Acquired | Provider of next-generation gene sequencing and multi-omics technologies | - | 60/100 | |
7th | Novogene Corporation 2011, Beijing (China), Series B | Provider of genomic services and solutions | $75M | 59/100 | |
8th | Replay 2021, San Diego (United States), Acquired | Provider of genomic reprogramming platform for writing and delivering big DNA | $55M | 58/100 | |
9th | Provider of bioinformatics tools for the analysis of genome sequencing data | $48.8M | 57/100 | ||
10th |  Enara Bio 2016, Oxford (United Kingdom), Series B | Developer of T-cell based cancer-cell interface for therapeutics | $84.1M | 53/100 | |
1030th | Provider of genomic services and solutions | - | - | 15/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Novogene's competitors? Click here to see the top ones
Novogene's Investments and acquisitions
Novogene has made no investments or acquisitions yet.
Reports related to Novogene
Here is the latest report on Novogene's sector:
Are you a Founder ?
FAQs about Novogene
Explore our recently published companies
- Bitolo - Tortola based, 2021 founded, Unfunded company
- BioLink Therapeutics - Bengaluru based, 2023 founded, Funding Raised company
- Bio-Combinator - Bengaluru based, 2023 founded, Funding Raised company
- Kentas Last & Schakt - Sweden based, 1985 founded, Public company
- Mehrotra Diagnostics - Kanpur based, Unfunded company
- Ikaros Solskydd - Sweden based, 2007 founded, Public company
